Rare diseases collectively affect hundreds of millions of people worldwide, yet most lack approved therapies. The economics of small patient populations have long stood in the way of intensive drug-discovery campaigns. We believe computation can fundamentally change that arithmetic.
Today we're announcing collaborations with three leading research centers to advance discovery efforts for genetically defined rare diseases. Our partners bring decades of disease-area expertise, validated targets, and clinical insight; we contribute platform capabilities that compress early-stage discovery from years into months.
Why rare disease
Many rare diseases have well-understood molecular causes — single-gene variants whose biology is interpretable and whose therapeutic strategies are tractable. They are exactly the kind of problem where a structurally informed, model-driven approach can shine, and where each successful program has a disproportionate impact on patient lives.
Looking ahead
We will share program-level updates as our work matures. In the meantime, we are deepening our biology team and adding capacity in chemistry and biophysics to support the partnerships. If you'd like to contribute to this work, we'd love to hear from you.